Crizotinib (Crizotinib) targeted drug price and actual cost analysis after medical insurance

Crizotinib, as a targeted drug, has been officially launched in China and included in medical insurance. Its market price is relatively high, but the actual cost can be significantly reduced after medical insurance reimbursement. This medicine is available in two specifications: 250mg 60 tablets and 200mg 60 tablets. Each box may be sold for more than 10,000 yuan. The specific price will vary slightly depending on hospitals, regions and pharmacies. For patients, although the original price is higher, after reimbursement through medical insurance, the out-of-pocket part will be significantly reduced, making the drug more accessible.

Under the domestic medical insurance system, the reimbursement ratio and out-of-pocket amount of crizotinib vary depending on the hospital level selected by the patient and regional policies. Generally, patients who qualify for medical insurance can enjoy a higher reimbursement rate, thereby reducing long-term treatment costs. When prescribing medicine, the doctor will recommend the most suitable specifications and dosage based on the patient's condition and medical insurance policy to ensure the efficacy while minimizing the patient's financial burden. Patients should confirm the specific reimbursement ratio and co-pay amount with the hospital pharmacy or medical insurance window before use, so as to make long-term medication planning.

In overseas markets, the price of the original drug crizotinib is also high, with each box selling for more than RMB 10,000. The price may change due to exchange rate fluctuations. In contrast, there are also relatively low-priced generic drugs overseas. These generic drugs have basically the same ingredients as the original drugs and can provide similar curative effects. For example, the generic drug of 250mg*60 tablets produced by Lucius Pharmaceuticals in Laos is priced at just over 1,000 yuan, providing patients with an economically feasible alternative. For patients who cannot afford the high cost of original drugs, generic drug channels have become an important supplement.

Overall, the actual cost of crizotinib after being reimbursed by medical insurance in China is much lower than the original selling price, allowing more patients to receive standardized targeted therapy. Although overseas original drugs are expensive, drugs can also be obtained at a lower cost through generic drug channels. When choosing medication channels, patients should comprehensively consider drug quality, price, medical insurance policies, and their own condition to ensure that they obtain the best curative effect while reducing their financial burden. Proper use of medical insurance and regular generic drug resources can achieve long-term sustainable use of crizotinib while ensuring safety.

Reference:https://en.wikipedia.org/wiki/Crizotinib